Market Overview

One Analyst's Top 5 Takeaways From Johnson & Johnson's Analyst Day

Related JNJ
A Hidden Gem Among Dividend ETFs
Wall Street's M&A Chatter From September 11: Western Digital-Toshiba, Pilgrim's Pride-Moy Park, Gigamon And More
The Vetr community has downgraded $JNJ to 2.5-Stars (Vetr)

Johnson & Johnson (NYSE: JNJ) hosted its annual analyst day earlier this week. Credit Suisse didn't see anything materially changing their view of the company's stock, but still had some notable takeaways.

  • "Strong commitment to broad footprint."
  • "Technology, innovation and business development overarching themes of the day."
  • "Consumer topline performance improving, with margin expansion likely to follow."
  • "JNJ also expecting accelerating market growth in Medical Devices."
  • "Attention now shifts back to Pharma at ASCO."

Credit Suisse holds a Neutral rating and $112 price target on shares. The stock closed Thursday at $112.85, down 0.6 percent.

Latest Ratings for JNJ

Jul 2017Atlantic EquitiesDowngradesNeutralUnderweight
Jul 2017BTIG ResearchDowngradesNeutralSell
Jul 2017Credit SuisseReinstatesOutperform

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Analyst Ratings


Related Articles (JNJ)

View Comments and Join the Discussion!